Age-specific changes in intrinsic breast cancer subtypes: A focus on older women

Oncologist

Volumn 19, Issue 10, 2014, Pages 1076-1083

  Jenkins, Emily O ^a   Deal, Allison M ^a   Anders, Carey K ^a   Prat, Aleix ^a   Perou, Charles M ^a   Carey, Lisa A ^a   Muss, Hyman B ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Age; Breast cancer; Elderly; Gene microarray

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROGESTERONE RECEPTOR; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR;

ADULT; AGED; AGING; ARTICLE; BASAL LIKE BREAST CANCER; BREAST CANCER; CLINICAL DECISION MAKING; DISEASE SPECIFIC SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; AGE; BREAST NEOPLASMS; CLASSIFICATION; GENE EXPRESSION PROFILING; PROCEDURES; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; YOUNG ADULT;

EID: 84929918938     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0184     Document Type: Article

References (41)

1. Altekruse SFKC, Krapcho M, Neyman N et al. SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute, 2010.
2. Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly womenwith breast cancer. J Natl Cancer Inst 2000; 92: 550-556.
3. Durbecq V, Ameye L, Veys I et al. A significant proportion of elderly patients develop hormonedependant "luminal-B" tumours associated with aggressive characteristics. Crit Rev Oncol Hematol 2008; 67: 80-92.
4. Walter LC, Covinsky KE. Cancer screening in elderly patients: A framework for individualized decision making. JAMA 2001; 285: 2750-2756.
5. Bastien RR, Rodriguez-Lescure A, Ebbert MT et al. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genomics 2012; 5: 44.
6. Nielsen TO, Parker JS, Leung S et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptorpositive breast cancer. Clin Cancer Res 2010; 16: 5222-5232.
7. Prat A, Cheang MC, Martin M et al. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal a breast cancer. J Clin Oncol 2013; 31: 203-209.
8. Ellis MJ, Suman VJ, Hoog J et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: Clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOGZ1031. J Clin Oncol 2011; 29: 2342-2349.
9. Anders CK, Hsu DS, Broadwater G et al. Young ageat diagnosis correlates withworseprognosisand defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 2008; 26: 3324-3330.
10. Dowsett M, Sestak I, Lopez-Knowles E et al. Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 2013; 31: 2783-2790.
11. Cheang MC, Voduc D, Bajdik C et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008; 14: 1368-1376.
12. Ellis MJ, Ding L, Shen D et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012; 486: 353-360.
13. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
14. Buffa FM, Camps C, Winchester L et al. MicroRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res 2011; 71: 5635-5645.
15. Anders CK, Acharya CR, Hsu DS et al. Agespecific differences in oncogenic pathway deregulation seen in human breast tumors. PLoS One 2008; 3: e1373.
16. WangY, Klijn JG, Zhang Y et al. Gene-expression profilesto predictdistantmetastasis oflymph-nodenegative primary breast cancer. Lancet 2005; 365: 671-679.
17. Ivshina AV, George J, Senko O et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 2006; 66: 10292-10301.
18. Hatzis C, Pusztai L, Valero V et al. A genomic predictor of response and survival following taxaneanthracycline chemotherapy for invasive breast cancer. JAMA 2011; 305: 1873-1881.
19. Minn AJ, Gupta GP, Siegel PM et al. Genes that mediate breast cancer metastasis to lung. Nature 2005; 436: 518-524.
20. Sotiriou C, Wirapati P, Loi S et al. Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006; 98: 262-272.
21. Prat A, Parker JS, KarginovaO et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12: R68.
22. Curtis C, Shah SP, Chin SF et al. The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 2012; 486: 346-352.
23. Parker JS, Mullins M, Cheang MC et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-1167.
24. Perou CM, Parker JS, Prat A, Ellis MJ, Bernard PS. Clinical implementation of the intrinsic subtypes of breast cancer. Lancet Oncol 2010; 11: 718-719.
25. Prat A, Parker JS, Fan C, Perou CM. PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer. Breast Cancer Res Treat 2012; 135: 301-306.
26. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011; 5: 5-23.
27. Morrison DHRD, Rahardja D, King E et al. Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer. Br J Cancer 2012; 107: 382-387.
28. Ihemelandu CULL, Leffall LD Jr., Dewitty RL et al. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: Age-specific prevalence and survival. J Surg Res 2007; 143: 109-118.
29. Ring A, Sestak I, Baum M et al. Influence of comorbidities and age on risk of death without recurrence: Aretrospective analysis of the arimidex, tamoxifen alone or in combination trial. J Clin Oncol 2011; 29: 4266-4272.
30. Muss HB, Woolf S, Berry D et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005; 293: 1073-1081.
31. Anders CKFC, Fan C, Parker JS et al. Breast carcinomas arising at a young age: Unique biology or a surrogate for aggressive intrinsic subtypes? J Clin Oncol 2011; 29: e18-e20.
32. Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with nodenegative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24: 3726-3734.
33. Drukker CA, van Tinteren H, Schmidt MK et al. Long-term impact of the 70-gene signature on breast cancer outcome. Breast Cancer Res Treat 2014; 143: 587-592.
34. Prat A, Bianchini G, Thomas M et al. Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study. Clin Cancer Res 2014; 20: 511-521.
35. Dunbier AK, Anderson H, Ghazoui Z et al. Association between breast cancer subtypes and response to neoadjuvant anastrozole. Steroids 2011; 76: 736-740.
36. Esserman LJ, Berry DA, Cheang MC et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 2012; 132: 1049-1062.
37. Martín M, Prat A, Rodríguez-Lescure A et al. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. BreastCancer Res Treat 2013; 138: 457-466.
38. Jones EL, Leak A, MussHB. Adjuvant therapy of breast cancer in women 70 years of age and older: Tough decisions, high stakes. Oncology (Williston Park) 2012; 26: 793-801.
39. Yourman LCLS, Lee SJ, Schonberg MA et al. Prognostic indices for older adults: A systematic review. JAMA 2012; 307: 182-192.
40. Lewis JHKM, Kilgore ML, Goldman DP et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003; 21: 1383-1389.
41. Hyman Muss, Javier Cortes, Linda T. Vahdat et al. Eribulin Monotherapy in Patients Aged 70 Years and Older With Metastatic Breast Cancer. The Oncologist 2014; 19: 318-327.